Sensulin
- Mike MoradiCo-founder & Chief Executive Officer · Company website
- Ananth Annapragada, PhDCo-Founder & Chief Scientist · Company website
- Chris A. Rhodes, PhDCo-Founder & Chief Technology Officer · Company website
- Jon BrilliantChief Financial Officer · Company website
How we got $758K
Based on typical figures for its industry (2022 Economic Census), not its own records.
What we know
What they do
Sensulin is a preclinical biopharmaceutical company developing a glucose-responsive insulin for type 1 and type 2 diabetes. It aims to lower the risk of hypoglycemia and reduce the number of daily injections.
From the company's website. Industry: Research and Development in Biotechnology (except Nanobiotechnology).
Compared with similar businesses nearby
| Business | Est. revenue | Distance |
|---|---|---|
| Sensulin this business | $2.0M | — |
| Arl Biopharma, Inc. Oklahoma City | $1.5M | 0.0 mi |
| Oklahoma Bioscience Association (okbio) Oklahoma City | $1.5M | 0.1 mi |
| Biolytx Pharmaceuticals Corp Oklahoma City | $1.5M | 0.1 mi |
| Oklahoma Center for the Advancement of Science and Technology (OCAST) Oklahoma City | $1.5M | 0.1 mi |
| COARE BIOTECHNOLOGY Oklahoma City · 3 employees | $1.8M | 0.1 mi |
| DRIK, LLC Oklahoma City · 2 employees | $952K | 0.1 mi |
Ranges & sources
This business has no PPP loan on record, so there is no business-specific data. The figures are the typical estimated revenue of Research and Development in Biotechnology (except Nanobiotechnology) businesses in our Oklahoma data: the middle value, with the range covering the middle half of those businesses. EBITDA applies the industry margin (13%). Treat these as a rough guide.
| Revenue range | $586K – $3.1M |
| EBITDA range | $75K – $393K |
| Industry (NAICS) | Research and Development in Biotechnology (except Nanobiotechnology) (541714) |
| Value range | $180K – $1.4M |
EBITDA margin: from IRS tax returns of S corporations in this industry (2019–2022), adjusted for company size: smaller companies typically run higher margins. EBITDA here is after owners' salaries.
Benchmarks: US Economic Census 2022. These are statistical estimates, not reported financials. Listing details come from Overture Maps open data. Full methodology
Public records
Matched to this business by name and address from public government data; a match can occasionally be wrong.
About Sensulin
Sensulin is a research and development in biotechnology (except nanobiotechnology) company in Oklahoma City, Oklahoma, in business since 2012. It is owned by Dan Bradbury (Co-Founder). Its estimated annual revenue is about $2.0M, with roughly $253K of EBITDA. Its estimated business value is $758K (likely range $180K–$1.4M).
Common questions
- Who owns Sensulin?
- Sensulin is owned by Dan Bradbury (Co-Founder), according to public sources such as the company's website or filings.
- How much revenue does Sensulin make?
- SeeBITDA estimates Sensulin's annual revenue at about $2.0M (likely between $586K and $3.1M), based on public records such as its PPP loan and retirement-plan filings, brought up to 2026.
- What is Sensulin worth?
- About $758K, roughly 3× its estimated EBITDA of $253K, typical for a research and development in biotechnology (except nanobiotechnology) company its size. Likely range: $180K–$1.4M.
- When was Sensulin founded?
- Sensulin has been in business since 2012.